The secondary endpoints included the serum follicle-stimulating hormone (FSH), total testosterone, luteinizing hormone (LH), estradiol, and homeostasis model assessment insulin resistance (HOMA-IR).<h4>Results</h4>There were 16 RCTs with 1,385 patients identified. This evidence concerns the gene PLOD1 and Insulin resistance.